Angel One - Share Market Trading and Stock Broking
Open Demat AccountLogin

Divis Laboratories Share Price Live

DIVISLAB

Large Cap | Pharmaceuticals

₹ 6667.00

-130.50(1.92%)

Live Divis Laboratories Share Price Chart

Divis Laboratories Performance

Days Range

Previous Close₹6,797.50
Open₹6,800
Volume6,11,999
Day's Range₹6,590.00 - ₹6,849.00
52W Range₹5,636.50 - ₹7,071.50
Market Cap₹1,76,807.38 Cr

Divis Laboratories Fundamentals

ROCE(TTM)19.56
P/E Ratio (TTM)68.85
P/B Ratio10.55
Industry P/E33.73
Debt to EquityN/A
ROE15.32
EPS (TTM)98.81
Dividend Yield0.45
Book Value631.38
Face Value2
ROCE(TTM)19.56
P/E Ratio (TTM)68.85
P/B Ratio10.55
Industry P/E33.73
Debt to EquityN/A
ROE15.32
EPS (TTM)98.81
Dividend Yield0.45
Book Value631.38
Face Value2

Divis Laboratories Financials

Jun 2025Sep 2025Dec 2025Mar 2026
Net Sales2,410.002,715.002,604.002,831.00
Expenses1,793.001,940.001,832.002,017.00
Profit before tax733.00912.00780.00963.00
Operating Profit545.00689.00583.00751.00
Net Profit545.00689.00583.00751.00
EPS in Rs20.4925.9724.7728.31

Divis Laboratories Shareholding Pattern

Held byMar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters51.89%51.89%51.89%51.88%51.88%
Flls18.01%19.74%19.39%20.08%20.29%
Dlls20.71%19.05%19.76%19.28%19.22%
Public9.39%9.32%8.96%8.76%8.61%

About Divis Laboratories

History of Divis Laboratories

Divi’s Research Centre was established in 1990, and its first manufacturing facility was built in 1995 near Hyderabad. The centre had been built with research and development as its primary goal. During 1991-93, the company successfully developed several commercial processes for intermediates and bulk actives. In the year 1994, the company changed its name to Divis Laboratories Ltd to reflect their growing area of operations. In 2003, a new research centre named 'DRC-Vizag' was built by the company for research in more niche segments.  In 2003, Divi’s Laboratories was listed on the Indian stock exchanges. In 2006-07, Divi’s developed an SEZ titled 'Divi's Pharma SEZ' near Visakhapatnam. In the following year, the company set up production and utility facilities in the SEZ and EOU units. They commissioned a Nutraceuticals Manufacturing facility at Divi's Pharma SEZ. In 2023, the company set up a third manufacturing plant (Unit-III) in Kakinada, Andhra Pradesh. Over the years, the company has passed multiple inspections by the USFDA as well as other major drug inspection agencies of foreign countries.

Divis Laboratories Business Segments

Divi’s Laboratories manufactures generic and customised active pharmaceutical ingredients (APIs) and intermediates along with Nutraceuticals for a global audience. Their business segments can be categorised as:
  1. Generic APIs: These include large volumes of standard medicine in tens to thousands of tonnes each year, exported to over 100 countries. Divi’s manufactures 30 APIs commercially, and 10 more APIs are in various stages of R&D/pilot project stage. Divi’s is one of the top 2 API manufacturers globally for 18 out of these 30 molecules.
  2. Custom Synthesis: These include APIs that have been custom-built based on the requirements of major clients. 12 out of the top 20 companies across the US, EU and Japan have been clients of Divi’s for over 10 years.
  3. Nutraceutical: The company's Vishakhapatnam unit produces Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. The company also offers customised ingredient solutions in liquids, beadlets and powder forms.
Overall, its product categories include antidepressants, antineoplastic, anti-Parkinson, anti-hypersensitive, analgesic, anticonvulsant/neuropathic pain, anti-inflammatory drugs, etc. As of March 31, 2023, the company has two overseas subsidiaries, namely M/s. Divis Laboratories (USA) Inc., in the US and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products.

Divis Laboratories Management Team

Dr. Murali K. Divi, Founder and Managing Director Dr. Divi is the Founder and Managing Director of Divi’s Laboratories Ltd. He oversees major technical and financial operations of the company. Before starting Divi’s, Dr. Divi had more than 15 years of experience in the pharma industry and has led various global research and manufacturing teams. He holds a Ph.D. degree in Pharmaceutical Sciences from Kakatiya University and is also a member of the American Institute of Chemical Engineers and the American Chemical Society. Dr. Kiran S. Divi, CEO Dr. Kiran Divi is the Director on the Board and is the Chief Executive Officer at Divi’s Laboratories Ltd. He has been with Divi’s for the past 20 years. He took charge as the as the CEO in January 2020. He studied Pharmacy at JNTU, India and also holds a Ph.D. degree from the Gandhi Institute of Technology and Management, Visakhapatnam.

Divis Laboratories Corporate Action

Bonus Shares Divi’s Laboratories had announced bonus shares last in 2015, in the ratio of 1:1. Before that, it had issued a 1:1 bonus share as well, in 2009. Stock Split Divis Laboratories had split the face value of its shares from ₹10 to ₹2 in 2007.

Divis Laboratories Financial Highlights

  • The company has steadily increased its total revenue from ₹816 crore in March 2013 to ₹2,370 crore in March 2023.
  • The company has a large amount of assets. As of September 2023, its current ratio and quick ratio are 8.46 and 5.73, respectively.
  • The company has consistently increased its investment in land, building and plant and machinery. 
  • It has also built up a massive inventory and trade receivables, which contributes to a large current ratio.

Parent Organisation
Indian Private
Managing Director
Murali K Divi
Founded
1990
NSE Symbol
DIVISLAB

Divis Laboratories Share Price History

ParticularsDetails
5-Year % change in Divis Laboratories share price167.78%
5-Year Highest in Divis Laboratories share price₹ 6308.5
5-Year Lowest in Divis Laboratories share price₹ 2090.05
1-Year % change in Divis Laboratories share price56.87%
1-Year Highest in Divis Laboratories share price₹ 6308.5
1-Year Lowest in Divis Laboratories share price₹ 3724

Peer Comparison

StocksLTP (₹)Market Cap (cr)52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd1,799.2
-45.10 (-2.45%)		₹4,32,096.231,548.0 - 1,916.6View Stocks
Torrent Pharmaceuticals Ltd4,410.8
-127.00 (-2.80%)		₹1,48,718.003,102.0 - 4,712.9View Stocks
Cipla Ltd1,401.0
-17.20 (-1.21%)		₹1,12,970.911,165.7 - 1,673.0View Stocks
Dr Reddys Laboratories Ltd1,303.5
-15.50 (-1.18%)		₹1,08,751.631,148.4 - 1,379.7View Stocks
Zydus Lifesciences Ltd1,077.7
-8.10 (-0.75%)		₹1,08,441.84835.5 - 1,115.5View Stocks
Lupin Ltd2,267.7
-8.70 (-0.38%)		₹1,03,900.021,836.8 - 2,494.0View Stocks

Divis Laboratories Latest News

Live Market Data: Divis Laboratories Ltd Share Price Down -1.81% Today

Divis Laboratories Ltd shares saw a -1.81% decrease, reaching a current market price of 6674.50. Investors are keeping a close watch on this development, looking for potential signals of a turnaround. The stock has a PE ratio of 70.2700, an ROE of 15.3213 and a debt to equity ratio of 0.0004.

Today's Trading Session: Divis Laboratories Ltd Share Price Declines by -0.78%

Divis Laboratories Ltd experienced a -0.78% downturn in its share price, and it's currently trading at 6744.50. This situation is generating interest among value investors who are evaluating the stock's potential.

Today's Trading Session: Divis Laboratories Ltd Share Price Declines by -0.78%

Divis Laboratories Ltd experienced a -0.78% downturn in its share price, and it's currently trading at 6744.50. This situation is generating interest among value investors who are evaluating the stock's potential.

Divis Laboratories Ltd FAQs

Divis Laboratories Ltd (DIVISLAB) share price as of May 29, 2026, on NSE is Rs 6667 (NSE) and Rs 6667 (BSE) on BSE.
Yes, You can buy Divis Laboratories Ltd (DIVISLAB) shares by opening a Demat account with Angel One.
Divis Laboratories Ltd (DIVISLAB) share can be bought through the following modes:
1. Direct investment: You can buy Divis Laboratories Ltd (DIVISLAB) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Divis Laboratories Ltd (DIVISLAB) shares.
The business produces top generic chemicals used as nutraceutical components and produces APIs and intermediates on demand for prominent international innovation firms.
The owner of Divis Labs is Divi Murali. He is the Chairman and CEO of Divis Laboratories.
The promoters are Nilima Motaparti, Satchandra Kiran Divi, Nilima Prasad Divi, Swarna Latha Divi, Divi'S Biotech Private Limited, Murali Krishna Prasad Divi, Madhusudana Rao Divi, Babu Rajendra Prasad Divi, Radhakrishna Rao Divi.
The market cap of Divis Laboratories is Rs. 176807.38 Cr. as of 30/05/2026.
The P/E ratios of Divis Laboratories is 68.85 as of 30/05/2026.
The PB ratios of Divis Laboratories is 10.55 as of 30/05/2026.

Related News

View All
CCI Clears Creation of JV Company Between Mercuria Energy Netherlands and Tata International Singapore

Share Market

CCI Clears Creation of JV Company Between Mercuria Energy Netherlands and Tata International Singapore

May 27, 2026
Jindal India Completes ₹1,500 Crore Expansion Project in West Bengal with New Coating Facility

Share Market

Jindal India Completes ₹1,500 Crore Expansion Project in West Bengal with New Coating Facility

May 20, 2026
Consumer Goods Makers Including Hindustan Unilever and Dabur Expect Volume Led Growth as Inflation Eases

Share Market

Consumer Goods Makers Including Hindustan Unilever and Dabur Expect Volume Led Growth as Inflation Eases

February 24, 2026
Open Free Demat Account!
Join our 3.5 Cr+ happy customers